Empros first clinical trial, closed in 2017 was recently published in Obesity Science and Practice, see full text article here. In this phase 2a trial Empros compared three different doses of EMP16 to Xenical. The trial demonstrated that EMP16 is safe and has an improved tolerability. Through questionnaires we observed a decreased hunger.
With these positive results Empros decided to proceed with the next randomized, double blinded, placebo controlled phase 2a trial during 2020 and 2021.